Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/61143
Title: Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study.
Author: Ripoll, Cristina
Genescà, Joan
Araujo, Isis K.
Graupera, Isabel
Augustin, Salvador
Tejedor, Marta
Cirera, Isabel
Aracil, Carles
Sala, Margarita
Hernandez-Guerra, Manuel
Llop, Elba
Escorsell i Mañosa, M. Àngels
Catalina, M. V.
Cañete, Núria
Albillos, Agustín
Villanueva Sánchez, Càndid
González-Abraldes Iglesias, Juan
Bañares, Rafael
Bosch i Genover, Jaume
Keywords: Càncer de fetge
Varices esofàgiques
Assaigs clínics
Epidemiologia
Liver cancer
Esophageal varices
Clinical trials
Epidemiology
Issue Date: 15-Oct-2013
Publisher: Wiley
Abstract: Outcome of variceal bleeding (VB) in patients with hepatocellular carcinoma (HCC) is unknown. We compared outcomes after VB in patients with and without HCC. All patients with HCC and esophageal VB admitted between 2007 and 2010 were included. Follow-up was prolonged until death, transplantation, or June 2011. For each patient with HCC, a patient without HCC matched by age and Child-Pugh class was selected. A total of 292 patients were included, 146 with HCC (Barcelona Classification of Liver Cancer class 0-3 patients, A [in 25], B [in 29], C [in 45], and D [in 41]) and 146 without HCC. No differences were observed regarding previous use of prophylaxis, clinical presentation, endoscopic findings, and initial endoscopic treatment. Five-day failure was similar (25% in HCC versus 18% in non-HCC; P = 0.257). HCC patients had greater 6-week rebleeding rate (16 versus 7%, respectively; P = 0.025) and 6-week mortality (30% versus 15%; P = 0.003). Fewer patients with HCC received secondary prophylaxis after bleeding (77% versus 89%; P = 0.009), and standard combination therapy was used less frequently (58% versus 70%; P = 0.079). Secondary prophylaxis failure was more frequent (50% versus 31%; P = 0.001) and survival significantly shorter in patients with HCC (median survival: 5 months versus greater than 38 months in patients without HCC; P < 0.001). Lack of prophylaxis increased rebleeding and mortality. On multivariate analysis Child-Pugh score, presence of HCC, portal vein thrombosis, and lack of secondary prophylaxis were predictors of death. Conclusions: Patients with HCC and VB have worse prognosis than patients with VB without HCC. Secondary prophylaxis offers survival benefit in HCC patients
Note: Versió postprint del document publicat a: http://dx.doi.org/10.1002/hep.26629
It is part of: Hepatology, 2013, vol. 58, num. 6, p. 2079-2088
Related resource: http://dx.doi.org/10.1002/hep.26629
URI: http://hdl.handle.net/2445/61143
ISSN: 0270-9139
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
638268.pdf2.42 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.